The Food and Drug Administration’s approval of Ozempic in 2021 for weight loss treatment ushered in a new era for the class ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Scientists may have discovered a way to naturally regulate blood sugar levels and sugar cravings that works similarly to ...

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health ...

Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are secreted from the same intestinal cells following meal ingestion. GLP-1 is now widely recognised to reduce blood glucose levels ...

With glucagon-like peptide 1 (GLP-1) agonists now close to inducing weight loss at levels only seen before through surgical intervention, obesity specialists say patients on these drugs are ...

Studies suggest that the peptide may activate receptors involved in energy balance, such as the glucagon-like peptide-1 (GLP-1) receptor, glucagon receptor (GCGR), and glucose-dependent ...